Advanced Biomed (NASDAQ:ADVB) Releases Earnings Results

Posted by Geri Gentry on Oct 15th, 2026

Advanced Biomed (NASDAQ:ADVB – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.44 EPS for the quarter, FiscalAI reports.

Advanced Biomed Stock Performance

Advanced Biomed stock opened at $5.14 on Thursday. Advanced Biomed has a 1 year low of $3.61 and a 1 year high of $24.23. The firm’s 50-day moving average is $7.65 and its 200-day moving average is $6.46. The company has a market cap of $8.49 million, a P/E ratio of 1.07 and a beta of 0.01.

Wall Street Analyst Weigh In

Several analysts have issued reports on ADVB shares. Wall Street Zen upgraded Advanced Biomed to a “hold” rating in a research note on Saturday, August 22nd. Weiss Ratings downgraded Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Advanced Biomed currently has an average rating of “Sell”.

Get Our Latest Analysis on ADVB

Advanced Biomed Company Profile

(Get Free Report)

Advanced Biomed Inc is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer.

The company’s research is centered on radioligand therapies, which use targeting molecules to deliver radioactive substances directly to cancer cells. Its development programs include products designed to target prostate-specific membrane antigen (PSMA), an established target in prostate cancer.

Advanced Biomed’s programs remain subject to clinical development and regulatory review.